<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291898</url>
  </required_header>
  <id_info>
    <org_study_id>ASDdevices</org_study_id>
    <nct_id>NCT04291898</nct_id>
  </id_info>
  <brief_title>Comparison of Devices for Atrial Septal Defects Closure: A Pilot Study</brief_title>
  <acronym>Trio-ASD</acronym>
  <official_title>Comparative Effectiveness of Three Devices for Transcatheter Closure of Atrial Septal Defects for Adults: A Pilot Study (Trio-ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proposal, for the first time in Canada, to examine the comparative effectiveness of
      three commercially available atrial septal defect (ASD) devices in an internal pilot
      randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most widely used transcatheter device for ASD closure is the the Amplatzer Septal
      Occluder (ASO). Two new devices that entered the Canadian market are the Gore Cardioform ASD
      occluder (GAO) and the Figulla Flexible II Occlutech (FSO) device. There exists a paucity of
      data on the comparative efficacy and safety of these devices. This is a proposal, for the
      first time in Canada, to examine the comparative effectiveness of three commercially
      available ASD devices in an internal pilot randomized trial.

      Approximately 60 patients referred for transcatheter ASD closure will be recruited in this
      study over a period of 15 months from 4 participating centers across Canada. This will be a
      registry-based randomized controlled trial (RRCT) where patients will be enrolled into one of
      three arms (ASO, FSO, and GAO/GSO) to compare the effectiveness and safety outcomes of three
      different ASD closure devices.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to one of three arms for the duration of the study. The arms include: ASO, FSO, GAO/GSO which indicate the type of intervention they will be receiving.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Patients will be blinded to the device they receive. Healthcare providers or site coordinators cannot be blinded due to clear differences between devices.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of 'Clinical atrial fibrillation (AF)' or 'Major adverse cerebro-cardiovascular events (MACCE)</measure>
    <time_frame>24 weeks</time_frame>
    <description>At 24 weeks where clinical (AF) includes AF-related, ECG-documented, ED visit/hospitalization/physician visit, cardioversion, ablation or pacemaker implantation or new antiarrhythmic or AF anticoagulant prescription'; MACCE includes 'new onset heart failure (HF), HF-related ED admission, myocardial infarction, stroke, re-intervention, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days with &gt;6 min of AF detected on CardioSTAT monitor during 14 days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes with &gt;6 min of AF detected on CardioSTAT monitor during 14 days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time in AF during 14 days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time in AF during 14 days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute technical success rate at discharge, 24 weeks</measure>
    <time_frame>Discharge, 24 weeks</time_frame>
    <description>Successful deployment and retention without major device related complications, stroke, myocardial infarction (MI) or arrhythmia requiring antiarrhythmic drug or cardioversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful closure rate at discharge, 24 weeks</measure>
    <time_frame>Discharge, 24 weeks</time_frame>
    <description>Negative bubble study or residual shunt &lt;2mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device/procedure-related minor complications at discharge, 24 weeks</measure>
    <time_frame>Discharge, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device/procedure-related major complications at discharge, 24 weeks</measure>
    <time_frame>Discharge, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) using the EuroQoL (EQ-5D™) at baseline, 6 weeks, 24 weeks</measure>
    <time_frame>Baseline, 6 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) using the SF-12 questionnaire at baseline, 6 weeks, 24 weeks</measure>
    <time_frame>Baseline, 6 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilization at 6 and 24 weeks</measure>
    <time_frame>6 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the use of CardioSTAT and KardiaMobile devices using a Likert scale at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>1('not satisfied') to 5 ('very satisfied')</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Septal Defect</condition>
  <arm_group>
    <arm_group_label>Device: ASO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants implanted with the AMPLATZER™ Septal Occluder (ASO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device: FSO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants implanted with the Occlutech Figulla Flex II® (FSO).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device: GSO/GAO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMPLATZER™ Septal Occluder.</intervention_name>
    <description>Implantation of the AMPLATZER™ Septal Occluder in the ASD.</description>
    <arm_group_label>Device: ASO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech Figulla Flex II®</intervention_name>
    <description>Implantation of the Occlutech Figulla Flex II® in the ASD.</description>
    <arm_group_label>Device: FSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® CARDIOFORM ASD Occluder</intervention_name>
    <description>Implantation of the GORE® CARDIOFORM ASD Occluder in the ASD.</description>
    <arm_group_label>Device: GSO/GAO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old referred for percutaneous (secundum) ASD closure with right atrial and
             ventricular enlargement; and/or

          -  clinically significant left-to-tight shunt (Qp:Qs≥1.5:1), or

          -  evidence of paradoxical embolism (with a TEE defect &gt;10mm),

          -  written informed consent

        Exclusion Criteria:

          -  TEE defect diameter &gt;30mm,

          -  rim sizes of &lt; 5 mm to the coronary sinus, inferior vena cava rim, an atrioventricular
             valve, or the right upper pulmonary vein,

          -  multiple defects,

          -  complex congenital heart disease requiring surgical repair within 3 years of device
             placement,

          -  Eisenmenger-syndrome,

          -  recent myocardial infarction &lt; 6 weeks,

          -  demonstrated intra cardiac thrombi on echocardiography (especially LA or LAA thrombi),

          -  unable to have TEE,

          -  occluded bilateral femoral veins/IVC,

          -  serious comorbidity with life expectancy &lt;3 years (e.g., non-skin cancers not in
             remission, advanced renal failure serum creat &gt;160 [Symbol]mol/l),

          -  serious infection in ≤6 weeks producing bacteremia (e.g. sepsis), active endocarditis,
             or any other infection that cannot be treated successfully prior to device
             implantation (patient must have negative blood cultures off antibiotics for 1 week
             prior to procedure),

          -  active GI bleed &lt; 6 weeks,

          -  serious bleeding disorder,

          -  previous stroke,

          -  documented chronic atrial fibrillation or &gt;2 episodes of documented paroxysmal atrial
             fibrillation in the last 12 months,

          -  pregnancy or breastfeeding, plan to become pregnant before the end of the study
             period, not using an effective method of birth control in premenopausal women,

          -  documented nickel allergy,

          -  out of province residents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Horlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Peter Munk Cardiac Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lusine Abrahamyan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Theta Collaborative</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lusine Abrahamyan, MD, PhD</last_name>
    <phone>416-634-8782</phone>
    <email>lusine.abrahamyan@theta.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Horlick, MD</last_name>
    <email>eric.horlick@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronald Carere, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mounir Riahi, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Lusine Abrahamyan, MD, PhD</last_name>
      <email>lusine.abrahamyan@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Horlick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lusine Abrahamyan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal (MHI)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Reda Ibrahim, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anita Asgar, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie Et Pneumologie de Quebec/Hopital Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Josep R Cabau, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Eric Horlick</investigator_full_name>
    <investigator_title>Interventional and Congenital Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Transcatheter</keyword>
  <keyword>Closure</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>Atrial Septal Defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

